Depression and Parkinson’s disease
E. R. Bukhurova,
B. A. Alipkhanova,
D. Z. Shanibova
и другие.
Vestnik nevrologii psihiatrii i nejrohirurgii (Bulletin of Neurology Psychiatry and Neurosurgery),
Год журнала:
2024,
Номер
8, С. 982 - 991
Опубликована: Авг. 17, 2024
Parkinson's
disease
is
a
progressive
neurodegenerative
with
motor
symptoms
and
non-motor
impairments,
including
depression,
observed
in
2.7-90%
of
cases.
Depression
frequently
underestimated
diagnosed
late
due
to
its
similarity
disease,
such
as
fatigue,
sleep
disturbances,
hypomimia,
etc.
In
approximately
25%
patients,
depression
precedes
symptoms,
which
may
indicate
connection
the
pathogenesis
disease.
The
purpose
study
was
analyze
current
data
on
pathophysiology,
diagnosis,
treatment
patients
results
have
demonstrated
that
pathophysiological
mechanisms
include
neurodegeneration
dopaminergic,
noradrenergic,
serotonergic
neurons,
neuroinflammation,
impaired
neuroplasticity.
For
timely
treatment,
especially
those
changes
or
should
be
regularly
examined.
Treatment
based
multimodal
approach
includes
use
supportive
psychotherapy
pharmacotherapy.
Alternative
methods
exercise,
cognitive
behavioral
therapy,
transcranial
magnetic
stimulation,
electroconvulsive
therapy
are
also
being
explored.
Thus,
requires
an
individualized
approach.
Further
research
into
this
problem
crucial
develop
improve
patient
management
algorithms.
Язык: Английский
New insights into the effects of serotonin on Parkinson's disease and depression through its role in the gastrointestinal tract
Spanish Journal of Psychiatry and Mental Health,
Год журнала:
2024,
Номер
unknown
Опубликована: Июль 1, 2024
Neuropsychiatric
and
neurodegenerative
disorders
are
frequently
associated
with
gastrointestinal
(GI)
co-pathologies.
Although
the
central
enteric
nervous
systems
(CNS
ENS,
respectively)
have
been
studied
separately,
there
is
increasing
interest
in
factors
that
may
contribute
to
conditions
affecting
both
systems.
There
compelling
evidence
serotonin
(5-HT)
play
an
important
role
several
gut–brain
disorders.
It
well
known
5-HT
essential
for
development
functioning
of
CNS.
However,
most
body's
produced
GI
tract.
A
deeper
understanding
specific
effects
on
provide
basis
new
therapeutic
targets.
This
review
summarizes
current
data
focusing
ENS
motility,
particular
emphasis
novel
aspects
signaling
where
CNS
comorbidities
common,
such
as
Parkinson's
disease
depressive
Язык: Английский
Intranasal AdipoRon Mitigated Anxiety and Depression-Like Behaviors in 6-OHDA-Induced Parkinson ’s Disease Rat Model: Going Beyond Motor Symptoms
Neurochemical Research,
Год журнала:
2024,
Номер
49(11), С. 3030 - 3042
Опубликована: Авг. 3, 2024
Язык: Английский
Correlation of inflammatory markers with depression and sleep disorders accompanying the prodromal stage of Parkinson’s disease
World Journal of Psychiatry,
Год журнала:
2025,
Номер
15(3)
Опубликована: Фев. 26, 2025
Parkinson's
disease
(PD)
is
a
common
neurodegenerative
disorder
with
increasing
incidence
and
disability
rates
globally,
placing
heavy
burden
on
patients
their
families.
In
the
prodromal
phase
of
PD,
nonmotor
symptoms,
particularly
depression
sleep
disorders,
are
frequent,
profound
effects
progression
patient
quality
life.
Emerging
research
highlights
critical
role
inflammatory
markers-including
interleukins
tumor
necrosis
factor-in
pathogenesis
PD.
These
mediators
participate
in
processes
may
induce
or
exacerbate
depressive
symptoms
disorders
by
disrupting
function
hypothalamic-pituitary-adrenal
axis
affecting
neurotransmitter,
including
serotonin,
metabolism.
Understanding
correlations
PD
remains
incomplete,
limiting
our
ability
to
develop
targeted
interventions.
This
comprehensive
review
aims
investigate
specific
between
markers
symptoms-particularly
disorders-in
The
findings
could
have
important
practical
applications,
potentially
leading
development
new
diagnostic
tools
therapeutic
strategies
for
managing
By
identifying
understanding
these
correlations,
healthcare
providers
better
predict
implement
more
effective
treatments
Язык: Английский